HealthTree Logo
search more_vert
close
person Sign In / Create Account

Myelofibrosis is a serious bone marrow disorder that disrupts the body's normal production of blood cells. The staging and classification of myelofibrosis is based on the severity of symptoms, the presence of complications, and the patient's overall health status. The International Prognostic Scoring System (IPSS) and the Dynamic International Prognostic Scoring System (DIPSS) are commonly used to stage and classify myelofibrosis.

International Prognostic Scoring System (IPSS)

The IPSS is used at the time of diagnosis and includes five risk factors:

  1. Age over 65 years
  2. Presence of constitutional symptoms
  3. Hemoglobin level less than 10 g/dL
  4. Leukocyte count greater than 25 x 10^9/L
  5. Circulating blasts 1% or greater.

Each risk factor a patient has is assigned one point, and the total score determines the risk category: low (0 points), intermediate-1 (1 point), intermediate-2 (2 points), and high (3 or more points).

Dynamic International Prognostic Scoring System (DIPSS)

The DIPSS is used to reassess the disease stage at any time after diagnosis. It includes the same risk factors as the IPSS, but assigns two points for hemoglobin level less than 10 g/dL and for circulating blasts 1% or greater. The total score determines the risk category: low (0 points), intermediate-1 (1-2 points), intermediate-2 (3-4 points), and high (5 or more points).

Understanding the Phases of Myelofibrosis

Myelofibrosis can be divided into three phases: prefibrotic, overtly fibrotic, and advanced phase.

Prefibrotic Phase

In the prefibrotic phase, the bone marrow is hypercellular but fibrosis is not yet evident. Patients may have mild anemia and splenomegaly. This phase can last for several years.

Overtly Fibrotic Phase

In the overtly fibrotic phase, the bone marrow becomes fibrotic and the production of blood cells is impaired. Patients may have severe anemia, thrombocytopenia, and marked splenomegaly. This phase can last for several years to decades.

Advanced Phase

In the advanced phase, the disease progresses to acute myeloid leukemia (AML). Patients may have severe anemia, thrombocytopenia, and leukocytosis. The survival rate in this phase is often low.

Want to Learn More About Myelofibrosis?

Keep reading HealthTree for Myelofibrosis's 101 pages!

Myelofibrosis is a serious bone marrow disorder that disrupts the body's normal production of blood cells. The staging and classification of myelofibrosis is based on the severity of symptoms, the presence of complications, and the patient's overall health status. The International Prognostic Scoring System (IPSS) and the Dynamic International Prognostic Scoring System (DIPSS) are commonly used to stage and classify myelofibrosis.

International Prognostic Scoring System (IPSS)

The IPSS is used at the time of diagnosis and includes five risk factors:

  1. Age over 65 years
  2. Presence of constitutional symptoms
  3. Hemoglobin level less than 10 g/dL
  4. Leukocyte count greater than 25 x 10^9/L
  5. Circulating blasts 1% or greater.

Each risk factor a patient has is assigned one point, and the total score determines the risk category: low (0 points), intermediate-1 (1 point), intermediate-2 (2 points), and high (3 or more points).

Dynamic International Prognostic Scoring System (DIPSS)

The DIPSS is used to reassess the disease stage at any time after diagnosis. It includes the same risk factors as the IPSS, but assigns two points for hemoglobin level less than 10 g/dL and for circulating blasts 1% or greater. The total score determines the risk category: low (0 points), intermediate-1 (1-2 points), intermediate-2 (3-4 points), and high (5 or more points).

Understanding the Phases of Myelofibrosis

Myelofibrosis can be divided into three phases: prefibrotic, overtly fibrotic, and advanced phase.

Prefibrotic Phase

In the prefibrotic phase, the bone marrow is hypercellular but fibrosis is not yet evident. Patients may have mild anemia and splenomegaly. This phase can last for several years.

Overtly Fibrotic Phase

In the overtly fibrotic phase, the bone marrow becomes fibrotic and the production of blood cells is impaired. Patients may have severe anemia, thrombocytopenia, and marked splenomegaly. This phase can last for several years to decades.

Advanced Phase

In the advanced phase, the disease progresses to acute myeloid leukemia (AML). Patients may have severe anemia, thrombocytopenia, and leukocytosis. The survival rate in this phase is often low.

Want to Learn More About Myelofibrosis?

Keep reading HealthTree for Myelofibrosis's 101 pages!

Get the latest thought leadership on Myelofibrosis delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myelofibrosis Newsletter" for Myelofibrosis news, life with Myelofibrosis stories, Myelofibrosis clinical trials, Myelofibrosis 101 articles and events with Myelofibrosis experts.

Thanks to our HealthTree Community for Myelofibrosis Sponsors:

Karyopharm Therapeutics

Follow Us

facebook instagram youtube